Related Experiment Videos
The efficacy of high-dose 4'epidoxorubicin in hepatocellular carcinoma
Japanese Journal of Clinical Oncology
|September 1, 1988
Abstract:
An open phase II study of high-dose 4'epidoxorubicin (90 mg/m2) was conducted in 33 patients with inoperable hepatocellular carcinoma. Three out of the 33 (9%) patients showed tumour response. The treatment was relatively well tolerated with a moderate degree of haematological toxicity and alopecia, and a mild degree of nausea and vomiting. The overall median survival was 72 days with a prolongation in the patients who showed some response.